PATH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
UiPath is not a strong buy right now for a Beginner investor focused on the long term, even with $50,000-$100,000 available. The company is showing real operational improvement and AI-driven revenue momentum, but the stock is already extended in the near term and the analyst community remains mostly neutral to cautious. Because the investor is impatient and unwilling to wait for an optimal entry, this is still not an ideal buy today; the better call is to hold off rather than chase the pre-market dip.
PATH is in a short-term uptrend on momentum indicators, but the entry looks stretched. MACD histogram is positive and expanding, which supports bullish momentum. However, RSI_6 at 76.916 signals the stock is overbought in the near term, while moving averages are converging, suggesting the trend is not yet a clean, durable breakout. Price at 11.09 in pre-market is below the referenced current price of 11.58 and still below resistance at R1 11.775, with R2 at 12.457. Support sits at 10.671 pivot and 9.567 S1. Overall: constructive trend, but not a great fresh entry after the recent move.
UiPath reported strong Q1 fiscal 2027 results with ARR of $1.901 billion and revenue of $418 million, both above guidance. Non-GAAP EPS rose 36% year over year to $0.15, and revenue grew 17% year over year. News also points to strong AI growth and improving product traction, which is the main fundamental catalyst. Analyst commentary suggests better traction in large customers, stronger AI solution adoption, and improving execution.
Despite strong results, the stock is facing skepticism on the durability of AI monetization. Several firms cut price targets, including RBC, BMO, Evercore ISI, TD Cowen, DA Davidson, UBS, and Morgan Stanley, showing a downward reset in expectations. Consensus stance is mostly Hold/Neutral/Equal Weight, and multiple analysts want more evidence of sustained organic ARR growth and margin expansion. The recent pre-market drop of 4.23% suggests traders are taking profits after the earnings move. There is no significant hedge fund, insider, or congress trading support visible in the data.
Latest quarter: Q1 fiscal 2027. UiPath delivered revenue of $418.38 million, up 17% year over year, and non-GAAP EPS of $0.15, up 36% year over year. ARR reached $1.901 billion, exceeding guidance and showing continued growth in the subscription base. The quarter reflects healthier execution and strong AI-related demand, but the analyst feedback indicates investors still want clearer proof that this can translate into sustained organic net new ARR acceleration.
Recent analyst trend is mixed but mostly cautious. Price targets were cut across several firms: RBC to $12, BMO to $14, Evercore ISI to $13, TD Cowen to $13, DA Davidson to $13, UBS to $13, and Morgan Stanley to $17. Needham and Canaccord are more constructive, with Needham upgrading to Buy and Canaccord reiterating Buy, both around $15 targets. Wall Street’s pros see improving AI traction, stronger execution, margin expansion, and a more durable growth profile. The cons are that AI monetization is still not fully proven, organic net new ARR is still only stabilizing, and multiple firms believe the risk/reward is balanced rather than compelling.
